{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T21:43:40Z","timestamp":1793310220525,"version":"4.5.0"},"reference-count":25,"publisher":"American Medical Association (AMA)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA"],"published-print":{"date-parts":[[2026,7,14]]},"abstract":"\n Importance<\/jats:title>\n Osteogenesis imperfecta causes multiple fractures throughout life, causing substantial morbidity.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To determine whether the parathyroid hormone analogue teriparatide followed by zoledronic acid reduces the risk of fractures in adults with osteogenesis imperfecta.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n Multicenter open-label, parallel-group, randomized clinical trial, conducted between May 17, 2017, and March 21, 2025, in adults attending one of 27 referral centers with a clinical diagnosis of osteogenesis imperfecta. Bone mineral density (BMD) was measured by dual x-ray absorptiometry and bone turnover by serum procollagen type 1 N-terminal propeptide and C-terminal telopeptide of type 1 collagen. Fractures were confirmed by skeletal imaging. Several measures of health\u2013related quality of life were assessed.<\/jats:p>\n <\/jats:sec>\n \n Interventions<\/jats:title>\n Those in the active group received 20 \u03bcg of teriparatide daily by subcutaneous injection for 2 years followed by an infusion of 5 mg of zoledronic acid. In the standard care group, bisphosphonates and other bone-targeted medicines could be used but teriparatide and other bone anabolic drugs were prohibited.<\/jats:p>\n <\/jats:sec>\n \n Main outcomes and measures<\/jats:title>\n The primary end point was the number of participants with imaging-proven incident fractures adjudicated by reviewers blinded to treatment allocation. Secondary end points included the total number of fractures, changes in BMD, biochemical markers of bone turnover, and health\u2013related quality of life.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n Of the 350 individuals randomized, 176 were allocated to receive teriparatide plus zoledronic acid, 174 to standard care, and 1 withdrew, leaving 349 evaluable participants. The mean age was 43.7 years (188 females [53.9%]). Most had type I osteogenesis imperfecta caused by pathogenic variants in the type 1 collagen genes. In the teriparatide plus zoledronic acid group 65 of 176 (36.9%) had incident fractures compared with 63 of 173 (36.4%) in the standard care group (absolute risk reduction, \u20131.57%; 95% CI, \u20139.90% to 5.89%; hazard ratio, 0.97; 95% CI, 0.68 to 1.38). Lumbar spine and total hip BMD increased significantly more with teriparatide plus zoledronic acid than standard care. Several quality-of-life measures favored teriparatide plus zoledronic acid. Adverse events were similar in both groups.<\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n This randomized clinical trial among adults with osteogenesis imperfecta found that teriparatide plus zoledronic acid did not reduce fracture risk compared with standard care despite significantly increasing BMD, suggesting the importance of reduced bone quality rather than low bone density in the pathogenesis of fracture.<\/jats:p>\n <\/jats:sec>\n \n Trial Registration<\/jats:title>\n \n isrctn.org Identifier:\n ISRCTN15313991<\/jats:ext-link>\n <\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jama.2026.6889","type":"journal-article","created":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T15:32:19Z","timestamp":1778772739000},"page":"116","source":"Crossref","is-referenced-by-count":7,"title":["Teriparatide Plus Zoledronic Acid for Osteogenesis Imperfecta"],"prefix":"10.1001","volume":"336","author":[{"given":"Jannie Dahl","family":"Hald","sequence":"first","affiliation":[{"name":"Endocrinology, Aarhus University Hospital, Aarhus, Denmark"},{"name":"Centre for Rare Disorders, Aarhus University Hospital, Aarhus, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher J.","family":"Weir","sequence":"additional","affiliation":[{"name":"Edinburgh Clinical Trials Unit, Usher Institute, University of Edinburgh, Edinburgh, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catriona","family":"Keerie","sequence":"additional","affiliation":[{"name":"Edinburgh Clinical Trials Unit, Usher Institute, University of Edinburgh, Edinburgh, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorna","family":"Dewar","sequence":"additional","affiliation":[{"name":"Edinburgh Clinical Trials Unit, Usher Institute, University of Edinburgh, Edinburgh, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morag","family":"MacLean","sequence":"additional","affiliation":[{"name":"Edinburgh Clinical Trials Unit, Usher Institute, University of Edinburgh, Edinburgh, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynsey","family":"Milne","sequence":"additional","affiliation":[{"name":"Edinburgh Clinical Trials Unit, Usher Institute, University of Edinburgh, Edinburgh, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Keen","sequence":"additional","affiliation":[{"name":"Metabolic Bone Clinic, Royal National Orthopaedic Hospital NHS Trust, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer S.","family":"Walsh","sequence":"additional","affiliation":[{"name":"Metabolic Bone Centre, University of Sheffield, Sheffield, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth E. S.","family":"Poole","sequence":"additional","affiliation":[{"name":"Cambridge University Hospitals NHS Trust, Addenbrookes Hospital, Cambridge, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bente L.","family":"Langdahl","sequence":"additional","affiliation":[{"name":"Endocrinology, Aarhus University Hospital, Aarhus, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John R.","family":"Lindsay","sequence":"additional","affiliation":[{"name":"Belfast Health and Social Care Trust, Royal Victoria Hospital, and Musgrave Park Hospital, Belfast, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nazim","family":"Ghouri","sequence":"additional","affiliation":[{"name":"Queen Elizabeth University Hospital, Endocrinology, Glasgow, United Kingdom"},{"name":"University of Glasgow, Glasgow, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosemary","family":"Hollick","sequence":"additional","affiliation":[{"name":"Aberdeen Centre for Arthritis and Musculoskeletal Health (Epidemiology), University of Aberdeen, Aberdeen, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terry","family":"Aspray","sequence":"additional","affiliation":[{"name":"University of Newcastle, Bone Clinic- Freeman Hospital, Newcastle, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel K.","family":"Crowley","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, St Vincent\u2019s University Hospital, Dublin, Ireland"},{"name":"Rare Disease Clinical Trial Network, University College Dublin, Dublin, Republic of Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martine","family":"Cohen-Solal","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Inserm U1132 Bioscar, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zaki","family":"Hassan-Smith","sequence":"additional","affiliation":[{"name":"Aston Medical School, Aston University, Birmingham and Queen Elizabeth Hospital, Department of Endocrinology, Birmingham, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Tuck","sequence":"additional","affiliation":[{"name":"South Tees Hospitals NHS Foundation Trust, Rheumatology, Middlesborough, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth M.","family":"Curtis","sequence":"additional","affiliation":[{"name":"MRC Lifecourse Epidemiology Centre, University of Southampton, Southampton, United Kingdom"},{"name":"NIHR Southampton Biomedical Research Centre, University Hospital Southampton NHS Foundation Trust, Southampton, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas C.","family":"Harvey","sequence":"additional","affiliation":[{"name":"MRC Lifecourse Epidemiology Centre, University of Southampton, Southampton, United Kingdom"},{"name":"NIHR Southampton Biomedical Research Centre, University Hospital Southampton NHS Foundation Trust, Southampton, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth Marelise W.","family":"Eekhoff","sequence":"additional","affiliation":[{"name":"Amsterdam University Medical Centre, Endocrinology, Amsterdam, Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"Feenstra","sequence":"additional","affiliation":[{"name":"Isala Hospital Zwolle, Expert Centre for Osteogenesis Imperfecta in Adults, Zwolle, Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geeta","family":"Hampson","sequence":"additional","affiliation":[{"name":"Guys & St Thomas NHS Trust, Metabolic Bone Clinic, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mike","family":"Stone","sequence":"additional","affiliation":[{"name":"University Hospital Llandough, Metabolic Bone Clinic, Cardiff, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane","family":"Turton","sequence":"additional","affiliation":[{"name":"University Hospital Llandough, Metabolic Bone Clinic, Cardiff, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prashanth","family":"Patel","sequence":"additional","affiliation":[{"name":"University Hospitals of Leicester NHS Trust, Chemical Pathology and Metabolic Disease, Leicester, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mashood","family":"Siddiqi","sequence":"additional","affiliation":[{"name":"University Hospitals of Liverpool Group, Liverpool, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robin","family":"Munro","sequence":"additional","affiliation":[{"name":"University Hospital Wishaw, Wishaw, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Roy","sequence":"additional","affiliation":[{"name":"University Hospitals Bristol NHS Trust, Bristol Royal Infirmary, Bristol, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zoe","family":"Paskins","sequence":"additional","affiliation":[{"name":"Keele University, School of Medicine, Keele, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepa","family":"Narayanan","sequence":"additional","affiliation":[{"name":"The Centre for Metabolic Bone Disease, Hull University Teaching Hospitals NHS Trust, Hull, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellen","family":"Malcolm","sequence":"additional","affiliation":[{"name":"Ninewells Hospital and Medical School, Department of Medicine, Dundee, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Kassim","family":"Javaid","sequence":"additional","affiliation":[{"name":"Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Osborne","sequence":"additional","affiliation":[{"name":"Brittle Bone Society, Chief Executive Office, Dundee, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan C. Y.","family":"Tang","sequence":"additional","affiliation":[{"name":"Royal Free London NHS Foundation Trust London, United Kingdom"},{"name":"Institute of Genetics and Cancer, University of Edinburgh, Western General Hospital, Edinburgh, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wayne","family":"Lam","sequence":"additional","affiliation":[{"name":"South East Scotland NHS Genetics Service, Edinburgh, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Moore","sequence":"additional","affiliation":[{"name":"South East Scotland NHS Genetics Service, Edinburgh, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Holly A.","family":"Black","sequence":"additional","affiliation":[{"name":"South East Scotland NHS Genetics Service, Edinburgh, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew D.","family":"Duckworth","sequence":"additional","affiliation":[{"name":"Department of Orthopaedic Surgery, Royal Infirmary of Edinburgh, NHS Lothian, Edinburgh, United Kingdom"},{"name":"Centre for Population Health Sciences, Usher Institute, University of Edinburgh, Edinburgh, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Navni S.","family":"Makaram","sequence":"additional","affiliation":[{"name":"Department of Orthopaedic Surgery, Royal Infirmary of Edinburgh, NHS Lothian, Edinburgh, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianyu","family":"Guo","sequence":"additional","affiliation":[{"name":"Department of Radiology, Royal Infirmary of Edinburgh, NHS Lothian, Edinburgh, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregor","family":"Stenhouse","sequence":"additional","affiliation":[{"name":"Department of Radiology, Royal Infirmary of Edinburgh, NHS Lothian, Edinburgh, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stuart H.","family":"Ralston","sequence":"additional","affiliation":[{"name":"Institute of Genetics and Cancer, University of Edinburgh, Western General Hospital, Edinburgh, United Kingdom"},{"name":"Department of Rheumatology, Western General Hospital, NHS Lothian, Edinburgh, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"TOPaZ Investigators","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Conaghan","sequence":"additional","affiliation":[{"name":"for the TOPaZ Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Osten","family":"Llungren","sequence":"additional","affiliation":[{"name":"for the TOPaZ Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoper J","family":"Sutton","sequence":"additional","affiliation":[{"name":"for the TOPaZ Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eero","family":"Nevalainen","sequence":"additional","affiliation":[{"name":"for the TOPaZ Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Woolf","sequence":"additional","affiliation":[{"name":"for the TOPaZ Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzie","family":"Cro","sequence":"additional","affiliation":[{"name":"for the TOPaZ Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Willem","family":"Lema","sequence":"additional","affiliation":[{"name":"for the TOPaZ Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"6","key":"joi260039r1","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1007\/s00223-024-01236-x","article-title":"Osteogenesis imperfecta: skeletal and non-skeletal challenges in adulthood.","volume":"115","author":"Hald","year":"2024","journal-title":"Calcif Tissue Int"},{"issue":"1","key":"joi260039r2","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1002\/jbmr.2920","article-title":"Fracture rates and fracture sites in patients with osteogenesis imperfecta: a nationwide register-based cohort study.","volume":"32","author":"Folkestad","year":"2017","journal-title":"J Bone Miner Res"},{"issue":"5","key":"joi260039r3","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1002\/jbmr.2410","article-title":"Bisphosphonates for the prevention of fractures in osteogenesis imperfecta: meta-analysis of placebo-controlled trials.","volume":"30","author":"Hald","year":"2015","journal-title":"J Bone Miner Res"},{"issue":"10","key":"joi260039r4","article-title":"Bisphosphonate therapy for osteogenesis imperfecta.","volume":"10","author":"Dwan","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"issue":"4","key":"joi260039r5","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD005088.pub2","article-title":"Bisphosphonate therapy for osteogenesis imperfecta.","author":"Phillipi","year":"2008","journal-title":"Cochrane Database Syst Rev"},{"issue":"2","key":"joi260039r6","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1172\/JCI71101","article-title":"Evaluation of teriparatide treatment in adults with osteogenesis imperfecta.","volume":"124","author":"Orwoll","year":"2014","journal-title":"J Clin Invest"},{"issue":"2","key":"joi260039r7","doi-asserted-by":"publisher","first-page":"153","DOI":"10.11138\/ccmbm\/2017.14.1.153","article-title":"Efficacy of teriparatide vs neridronate in adults with osteogenesis imperfecta type I: a prospective randomized international clinical study.","volume":"14","author":"Leali","year":"2017","journal-title":"Clin Cases Miner Bone Metab"},{"issue":"11","key":"joi260039r8","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2023-078164","article-title":"Protocol of a randomised trial of teriparatide followed by zoledronic acid to reduce fracture risk in adults with osteogenesis imperfecta.","volume":"13","author":"Hald","year":"2023","journal-title":"BMJ Open"},{"issue":"1","key":"joi260039r9","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1007\/s00223-025-01440-3","article-title":"Baseline characteristics of the TOPaZ Study: randomised trial of teriparatide and zoledronic acid compared with standard care in adults with osteogenesis imperfecta.","volume":"116","author":"Hald","year":"2025","journal-title":"Calcif Tissue Int"},{"issue":"8072","key":"joi260039r10","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1016\/S0140-6736(78)90763-8","article-title":"Classification of osteogenesis imperfect","volume":"1","author":"Sillence","year":"1978","journal-title":"Lancet"},{"issue":"5","key":"joi260039r11","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/gim.2015.30","article-title":"Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology.","volume":"17","author":"Richards","year":"2015","journal-title":"Genet Med"},{"issue":"9","key":"joi260039r12","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1056\/NEJMoa044241","article-title":"Comparison of a single infusion of zoledronic acid with risedronate for Paget\u2019s disease.","volume":"353","author":"Reid","year":"2005","journal-title":"N Engl J Med"},{"issue":"1","key":"joi260039r13","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.jpain.2023.07.028","article-title":"Comparable minimally important differences and responsiveness of brief pain inventory and PEG pain scales across 6 trials.","volume":"25","author":"Reed","year":"2024","journal-title":"J Pain"},{"issue":"1","key":"joi260039r14","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1186\/s12955-024-02294-3","article-title":"Estimating the minimally important difference for the EQ-5D-5L and EORTC QLQ-C30 in cancer.","volume":"22","author":"Bourke","year":"2024","journal-title":"Health Qual Life Outcomes"},{"issue":"4","key":"joi260039r15","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1136\/aim.2009.000760","article-title":"Acupuncture and reflexology for insomnia: a feasibility study.","volume":"27","author":"Hughes","year":"2009","journal-title":"Acupunct Med"},{"issue":"9","key":"joi260039r16","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1136\/annrheumdis-2013-205079","article-title":"Clinically important changes in individual and composite measures of rheumatoid arthritis activity: thresholds applicable in clinical trials.","volume":"74","author":"Ward","year":"2015","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"joi260039r17","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1359\/JBMR.051015","article-title":"Effects of oral alendronate on BMD in adult patients with osteogenesis imperfecta: a 3-year randomized placebo-controlled trial.","volume":"21","author":"Chevrel","year":"2006","journal-title":"J Bone Miner Res"},{"issue":"1","key":"joi260039r18","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1359\/jbmr.2003.18.1.126","article-title":"Intravenous neridronate in adults with osteogenesis imperfecta.","volume":"18","author":"Adami","year":"2003","journal-title":"J Bone Miner Res"},{"issue":"1","key":"joi260039r19","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.jclinepi.2009.03.012","article-title":"Absolute risk reductions and numbers needed to treat can be obtained from adjusted survival models for time-to-event outcomes.","volume":"63","author":"Austin","year":"2010","journal-title":"J Clin Epidemiol"},{"issue":"20","key":"joi260039r20","doi-asserted-by":"publisher","first-page":"2028","DOI":"10.1056\/NEJMoa071408","article-title":"Teriparatide or alendronate in glucocorticoid-induced osteoporosis.","volume":"357","author":"Saag","year":"2007","journal-title":"N Engl J Med"},{"issue":"19","key":"joi260039r21","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1056\/NEJM200105103441904","article-title":"Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis.","volume":"344","author":"Neer","year":"2001","journal-title":"N Engl J Med"},{"issue":"2","key":"joi260039r22","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1007\/s00223-019-00563-8","article-title":"Long-term effects of teriparatide followed by antiresorptive therapy on clinical outcomes in patients with severe spinal osteoporosis.","volume":"105","author":"Oswald","year":"2019","journal-title":"Calcif Tissue Int"},{"issue":"8","key":"joi260039r23","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1016\/S2213-8587(20)30159-5","article-title":"Treatment-related changes in bone mineral density as a surrogate biomarker for fracture risk reduction: meta-regression analyses of individual patient data from multiple randomised controlled trials.","volume":"8","author":"Black","year":"2020","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"1","key":"joi260039r24","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1186\/s13023-024-03126-9","article-title":"The IMPACT survey: a mixed methods study to understand the experience of children, adolescents and adults with osteogenesis imperfecta and their caregivers.","volume":"19","author":"Westerheim","year":"2024","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"joi260039r25","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1002\/ajmg.a.63009","article-title":"A multicenter study to evaluate pain characteristics in osteogenesis imperfecta.","volume":"191","author":"Rodriguez Celin","year":"2023","journal-title":"Am J Med Genet A"}],"container-title":["JAMA"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/articlepdf\/2849063\/jama_hald_2026_oi_260039_1783020630.59734.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T15:00:26Z","timestamp":1784041226000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/fullarticle\/2849063"}},"subtitle":["A Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2026,7,14]]},"references-count":25,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,7,14]]}},"URL":"https:\/\/doi.org\/10.1001\/jama.2026.6889","relation":{},"ISSN":["0098-7484"],"issn-type":[{"value":"0098-7484","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7,14]]}}}